2026-05-22T00:53:35Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/180452024-11-28T15:05:55Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Avasthi, Ashish author Caro, Carlos author Pozo-Torres, Esther author Pernia Leal, Manuel author García-Martín, María Luisa author 2020-05-07 Iron oxide nanoparticles (IONPs) have emerged as a promising alternative to conventional contrast agents (CAs) for magnetic resonance imaging (MRI). They have been extensively investigated as CAs due to their high biocompatibility and excellent magnetic properties. Furthermore, the ease of functionalization of their surfaces with different types of ligands (antibodies, peptides, sugars, etc.) opens up the possibility of carrying out molecular MRI. Thus, IONPs functionalized with epithelial growth factor receptor antibodies, short peptides, like RGD, or aptamers, among others, have been proposed for the diagnosis of various types of cancer, including breast, stomach, colon, kidney, liver or brain cancer. In addition to cancer diagnosis, different types of IONPs have been developed for other applications, such as the detection of brain inflammation or the early diagnosis of thrombosis. This review addresses key aspects in the development of IONPs for MRI applications, namely, synthesis of the inorganic core, functionalization processes to make IONPs biocompatible and also to target them to specific tissues or cells, and finally in vivo studies in animal models, with special emphasis on tumor models. 10.1007/s41061-020-00302-w 2364-8961 2365-0869 Topics in Current Chemistry http://hdl.handle.net/10668/3377 32382832 http://hdl.handle.net/20.500.12105/18045 Magnetic nanoparticles Iron oxide nanoparticles Magnetic resonance imaging Cancer Diagnosis Nanopartículas magnéticas de óxido de hierro Imagen por resonancia magnética Neoplasias Diagnóstico Magnetic Nanoparticles as MRI Contrast Agents